论文部分内容阅读
目的研究进展性缺血性脑卒中治疗中应用氯吡格雷联合低分子肝素钙的临床价值。方法 90例进展性缺血性脑卒中患者,随机分为观察组与对照组,各45例,两组均接受低分子肝素钙治疗,观察组另外使用氯吡格雷,对比两组治疗前后神经功能及血流动力学。结果两组治疗后观察组神经功能评分为(10.15±1.87)分,显著低于对照组的(13.48±2.77)分,对比差异有统计学意义(P<0.05);血流动力学方面,治疗后观察组血浆粘度为(1.09±0.27)m Pa·s、纤维蛋白原(2.12±0.42)g/L、血小板聚集率(34.58±17.95)%显著低于对照组的(1.31±0.28)m Pa·s、(3.17±0.57)g/L、(50.61±19.88)%,观察组总有效率为71.11%高于对照组的48.89%,差异有统计学意义(P<0.05)。结论氯吡格雷联合低分子肝素钙治疗进展性缺血性脑卒中效果可靠,可显著改善患者的神经功能,使用血流动力学处于稳定状态,具有较高的临床推广价值。
Objective To study the clinical value of clopidogrel combined with low molecular weight heparin in the treatment of progressive ischemic stroke. Methods Ninety patients with progressive ischemic stroke were randomly divided into observation group and control group, 45 cases in each group. Both groups received low-molecular-weight heparin calcium. Clopidogrel was used in the observation group. Neurological function And hemodynamics. Results After treatment, the scores of neurological function in the observation group were (10.15 ± 1.87) points, which were significantly lower than those in the control group (13.48 ± 2.77), the difference was statistically significant (P <0.05); The hemodynamics, treatment The plasma viscosity of observation group was (1.09 ± 0.27) m Pa · s, fibrinogen (2.12 ± 0.42) g / L, and the platelet aggregation rate (34.58 ± 17.95)% was significantly lower than that of the control group (1.31 ± 0.28) mPa · S, (3.17 ± 0.57) g / L, (50.61 ± 19.88)% respectively. The total effective rate in the observation group was 71.11%, which was significantly higher than that in the control group (48.89%, P <0.05). Conclusion Clopidogrel combined with low molecular weight heparin calcium is a reliable and effective treatment for patients with progressive ischemic stroke. It can significantly improve the neurological function of patients with stable hemodynamics and has a high clinical value.